Business Wire

Octapharma Group Reports Strong Results for 2018

Del

Commenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “In 2018, we continued to drive growth in many of our products. I am particularly pleased with the important regulatory approvals for our new fibrinogen concentrate, fibryga®, which received regulatory approval in Switzerland, our new 10% IVIG product, panzyga®, approved for the US market, and our new SCIG product, cutaquig®, which was approved by both Health Canada and the FDA. These approvals are significant achievements for the company and, most importantly, bring substantial benefits to patients as well as physicians. Based on our strong product portfolio we are well positioned for the future.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190314005313/en/

Wolfgang Marguerre, Octapharma CEO and Chairman (Photo: Business Wire)

Wolfgang Marguerre, Octapharma CEO and Chairman (Photo: Business Wire)

Over the last seven years, the Octapharma Group has accomplished a remarkable compound annual growth rate of 14% and for 2018 reports sales of €1.797 billion – €77 million (4.5%) more than 2017’s figure (on a constant currency basis, the growth rate is 6.6%).

Gross profit in 2018 was €631 million, which is €39 million higher than achieved in 2017. Operating income was €346 million. The total operating expenses were €285 million. Significant investments were made for our future prosperity - €87 million for the R&D efforts and €153 million into the extension of the production capacity and infrastructure. The investments in research and infrastructure strongly position the company to fulfil the future needs of healthcare professionals and the increasing number of patients around the world.

In the last 12 months, several important milestones were reached in the expansion of the plasma and recombinant product portfolio. To ensure each litre of plasma is used to best effect, the company will continue to expand its product portfolio with innovative new products and services, and enter new markets.

Major projects within Program 2019, the development initiative launched in 2014 to double production capacity and significantly increase the overall efficiency of manufacturing operations, were completed and contributed to the company’s growth. The investments in talent, equipment and property prepare the company for the demands of the future.

“2018 was a year of strong execution at Octapharma,” said Roger Mächler, Chief Financial Officer of the company. “Our significant investments in research and infrastructure strongly position our company to fulfil the needs of more healthcare professionals and patients around the world.”

The Annual Report 2018 provides a comprehensive overview of the Octapharma Group, including our corporate governance and the financial results. To download the full Octapharma 2018 Annual Report visit www.annualreport.octapharma.com.

About Octapharma

The vision of Octapharma is: “Our passion drives us to provide new health solutions advancing human life”. Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood. Our company values are Ownership, Integrity, Leadership, Sustainability and Entrepreneurship.

In 2018, the Group achieved €1.8 billion in revenue, an operating income of €346 million and invested €240 million into R&D and in capital expenditures in order to ensure future prosperity. Octapharma employs 8 314 people worldwide to support the treatment of patients in 115 countries with products across three therapeutic areas:

  • Haematology (coagulation disorders)
  • Immunotherapy (immune disorders)
  • Critical care

Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden.

For more information visit www.octapharma.com

Contact information

Ivana Spotakova
Corporate Communications Manager
Octapharma AG | Seidenstrasse 2 | CH-8853 Lachen Switzerland |
Office: +41 (0)55 451 21 78 | Fax: +41 (0)55 451 21 62
ivana.spotakova@octapharma.com | www.octapharma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Elliott Statement on Uniper21.5.2019 12:04:00 CESTPressemelding

In advance of Uniper SE’s (“Uniper” or the “Company”) Annual General Meeting tomorrow, Elliott Advisors (UK) Limited has decided to withdraw its proposed resolution to instruct management to prepare a lawful domination agreement with the Company’s largest shareholder Fortum Oyj. About Elliott Elliott Management Corporation manages two multi-strategy funds which combined have approximately $34 billion of assets under management. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds of its kind under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Management Corporation. View source version on businesswire.com: https://www.businesswire.com/news/home/20190521005515/en/ Contact information London Sarah Rajani CFA Elliott Advisors (UK) Limited +44 (0) 20 3009 1475 srajani@

Rockefeller Capital Management Launches UCITS Funds Based on its Equity ESG Strategies21.5.2019 12:00:00 CESTPressemelding

Rockefeller Capital Management today announced that its asset management business, Rockefeller Asset Management, is now offering its long-standing equity investment capabilities that fully integrate Environmental, Social and Governance (ESG) research to European investors with the launch of a UCITS regulated fund structure. The first UCITS funds, seeded by prominent, long-term European institutional investors, are the Rockefeller Global ESG Equity Fund and the Rockefeller U.S. ESG Equity Fund (the “Funds”). The Funds are available to institutional and retail investors, featuring a founders’ share class for larger early-stage investors, and are available for passporting into many European countries. With investment roots in the U.S. dating back over 135 years and more than 30 years of experience in global equity investing, Rockefeller is a pioneer in combining a global investment view with a framework of rigorous fundamental research that incorporates ESG analysis. Rockefeller’s history

Moldova Citizenship-by-Investment Program Completes First Successful Application21.5.2019 09:07:00 CESTPressemelding

As concessionaire of the Moldova Citizenship-by-Investment (MCBI) program, Henley & Partners is pleased to note the successful completion of the first citizenship-by-investment application in the country. Henley & Partners has over 20 years of experience in strategic consulting, working with sovereign states around the globe in the design, set-up, and operation of the world’s most respected investment migration programs. The completion of the first citizenship-by-investment application process in Moldova clearly illustrates the features that are at the core of the MCBI program: impressive efficiency and a firm commitment to best practice. Within a three-month window, applicants are thoroughly screened in a multi-stage due diligence process that ensures only highly credible international investors are granted Moldovan citizenship. There are currently over 30 applications in process, which is a testament to the international investment community’s growing appreciation of the value of the

comforte AG Launches New Payments Industry Data Security Solution21.5.2019 08:50:00 CESTPressemelding

comforte AG today announced its Data Security Solution and Practice for the Payments Industry. The solution is making its debut at Card Forum 2019, the annual gathering of card and payment executives from the industry’s leading issuers, networks, retailers and innovators. Card Forum 2019 is being held this week in New Orleans. comforte AG has over a decade of history working with payment service providers (PSPs) to achieve compliance with data security regulations, in particular PCI DSS, as well as with more recent legislation such as the EU's General Data Protection Regulation (GDPR) or the upcoming California Consumer Privacy Act (CCPA). Our new solution will provide PSPs with enterprise-grade data security that not only fulfills key requirements of existing regulations, but will also help them to prepare for PSD2, which comes into effect in September of this year. PSD2 and open banking offer PSPs numerous opportunities to generate additional revenue, reduce costs, and increase marke

Lion/Gem Luxembourg 3 S.a.r.l. Announce Second Quarter Results for FY 201921.5.2019 08:00:00 CESTPressemelding

The Second Quarter Results for FY19 (to 30 September 2019) for Lion/Gem Luxembourg 3 S.a.r.l. (associated with Young’s Seafood Limited) will be made available on our Investor Relations website on May 21, 2019. The Second Quarter Results for FY19 call for investors that accompanies this information is scheduled to take place at 13:00 BST on May 21, 2019. The Second Quarter covers the quarter to 30 March 2019; the financial year end for Lion/Gem Luxembourg 3 S.a.r.l. is September 30, 2019. For further information: If you are an investor or a potential investor in the 8¼%/ 9% Senior PIK Notes due 2019, of Lion/Gem Luxembourg 3 S.a.r.l., and would like access to this information, please register your interest on our Investor Relations website: https://youngsseafood.co.uk/investors/. If you have any questions about the registration process or need further information, please do not hesitate to contact Nicholas Donnelly, Communications Manager at Young’s Seafood: nicholas.donnelly@youngsseaf

Arthur D. Little: Nord Stream 2 Provides Economic Benefits, Generates Innovation and Helps to Develop Contractors’ Businesses21.5.2019 08:00:00 CESTPressemelding

The second part of a recent report from Arthur D. Little (ADL) – “Nord Stream 2 economic impact in the construction phase” – analyzes the economic effects (job creation and GDP) of the ongoing project to build two new gas pipelines from Russia to Germany. The report, which is a follow-up to an earlier report created in 2017, analyzes the current status of project investment and concludes that the total economic benefit to the European Union (EU) represents €9.9 billion for building the pipelines. In comparison to the first report (2017), which was carried out in the procurement phase, more than twice as much CAPEX has now been committed and spent in several EU and non-EU countries now that the project is in the middle of construction. More than 1,000 contractors from all over Europe and Russia are contributing to the realization of the project. This includes both large international firms providing materials or construction services and small enterprises providing expert services. Furt